GeneDx completed a transformative acquisition of Fabric Genomics in May 2025, driving 40% revenue growth and a dramatic turnaround from negative to positive operating cash flow.
The Fabric Genomics merger has fundamentally transformed GeneDx's business scale and financial profile, with revenue jumping to $427.5M and the company achieving positive operating cash flow of $33.3M after years of cash burn. The acquisition appears highly accretive, significantly expanding GeneDx's AI capabilities and market position in genomics while improving operational efficiency.
GeneDx delivered exceptional financial performance driven by the Fabric Genomics acquisition, with revenue growing 40% to $427.5M and gross profit expanding 53% to $298.2M, indicating strong margin expansion. The company achieved a remarkable turnaround in cash generation, moving from -$28.5M to +$33.3M in operating cash flow while cutting net losses by 60% to -$21.0M despite higher R&D investment. The doubling of current liabilities and accounts receivable reflects the larger combined business scale, while increased capex suggests aggressive investment in growth infrastructure.
Capital expenditure jumped 246.3% — major investment cycle underway; assess returns on deployment.
Operating cash flow surged 216.8% — exceptional cash generation, highest quality earnings signal.
Current liabilities surged 98.7% — significant near-term obligations; verify ability to meet short-term debt.
Receivables surged 97.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income grew 59.8% — bottom-line growth signals improving overall business health.
R&D investment increased 57.5% — signals commitment to future product development, though near-term margin impact.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Strong top-line growth of 40% — accelerating demand or successful expansion into new markets.
Current assets grew 35.5% — improving short-term liquidity or inventory/receivables build.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →